These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 12467774

  • 1. Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance.
    Sarrazin C.
    J Clin Virol; 2002 Dec; 25 Suppl 3():S23-9. PubMed ID: 12467774
    [Abstract] [Full Text] [Related]

  • 2. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a.
    Sarrazin C, Hendricks DA, Sedarati F, Zeuzem S.
    J Clin Microbiol; 2001 Aug; 39(8):2850-5. PubMed ID: 11474002
    [Abstract] [Full Text] [Related]

  • 3. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays.
    Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S.
    Hepatology; 2000 Oct; 32(4 Pt 1):818-23. PubMed ID: 11003628
    [Abstract] [Full Text] [Related]

  • 4. Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay.
    Ferraro D, Giglio M, Bonura C, Di Marco V, Mondelli MU, Craxì A, Di Stefano R.
    J Viral Hepat; 2008 Jan; 15(1):66-70. PubMed ID: 18088247
    [Abstract] [Full Text] [Related]

  • 5. Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.
    Desombere I, Van Vlierberghe H, Couvent S, Clinckspoor F, Leroux-Roels G.
    J Clin Microbiol; 2005 Jun; 43(6):2590-7. PubMed ID: 15956369
    [Abstract] [Full Text] [Related]

  • 6. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment.
    Comanor L, Anderson F, Ghany M, Perrillo R, Heathcote EJ, Sherlock C, Zitron I, Hendricks D, Gordon SC.
    Am J Gastroenterol; 2001 Oct; 96(10):2968-72. PubMed ID: 11693334
    [Abstract] [Full Text] [Related]

  • 7. Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
    Roomer R, van Vuuren AJ, Schutten M, Heijens A, Janssen HL, de Knegt RJ.
    Antivir Ther; 2011 Oct; 16(5):771-4. PubMed ID: 21817199
    [Abstract] [Full Text] [Related]

  • 8. Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue.
    Hofmann WP, Dries V, Herrmann E, Gärtner B, Zeuzem S, Sarrazin C.
    J Clin Virol; 2005 Apr; 32(4):289-93. PubMed ID: 15780807
    [Abstract] [Full Text] [Related]

  • 9. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
    Akhan SC, Gurel E, Sayan M.
    Indian J Pathol Microbiol; 2011 Apr; 54(1):81-4. PubMed ID: 21393883
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
    Kessler HH, Pierer K, Santner BI, Vellimedu SK, Stelzl E, Marth E, Fickert P, Stauber RE.
    J Hum Virol; 1998 Apr; 1(5):314-9. PubMed ID: 10195258
    [Abstract] [Full Text] [Related]

  • 11. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.
    Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM, HALT-C Trial Group.
    Hepatology; 2008 Nov; 48(5):1412-9. PubMed ID: 18816437
    [Abstract] [Full Text] [Related]

  • 12. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
    Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, Castelnau C, Giuily N, El Ray A, Cardoso AC, Moucari R, Asselah T, Marcellin P.
    Hepatology; 2010 Apr; 51(4):1122-6. PubMed ID: 20069649
    [Abstract] [Full Text] [Related]

  • 13. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S.
    Ann Intern Med; 1997 Nov 15; 127(10):875-81. PubMed ID: 9382365
    [Abstract] [Full Text] [Related]

  • 14. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
    Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group.
    Hepatology; 2006 Aug 15; 44(2):360-7. PubMed ID: 16871570
    [Abstract] [Full Text] [Related]

  • 15. Prediction of the efficacy of antiviral therapy for hepatitis C virus infection by an ultrasensitive RT-PCR assay.
    Kinai E, Hanabusa H, Kato S.
    J Med Virol; 2007 Aug 15; 79(8):1113-9. PubMed ID: 17596840
    [Abstract] [Full Text] [Related]

  • 16. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
    Campos-Varela I, Castells L, Esteban JI, Bes M, Rodríguez-Frías F, Sapisochin G, Allende H, Charco R, Esteban R.
    Transplantation; 2012 Feb 27; 93(4):450-3. PubMed ID: 22262129
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N, Mehtap O, Gümrah M, Arican N.
    Turk J Gastroenterol; 2006 Jun 27; 17(2):94-8. PubMed ID: 16830289
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Low-level HCV viraemia after initial response during antiviral therapy: transcription-mediated amplification predicts treatment failure.
    Gelderblom HC, Reesink HW, Beld MG, Weegink CJ, Jansen PL, Dijkgraaf MG, Zaaijer HL.
    Antivir Ther; 2007 Jun 27; 12(3):423-7. PubMed ID: 17591033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.